Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.

Inclusion Criteria:

• Primary open-angle glaucoma in one eye
• Visual acuity 20/80 or better
• Intraocular pressure in the study eye ≤ 24 mm Hg
• Glaucomatous visual field loss - 7 dB to - 25 dB

Exclusion Criteria:

• Known allergy to brimonidine tartrate
• Uncontrolled systemic disease or infection of the eye
• Recent eye surgery or injections in the eye
• Female patients who are pregnant, nursing or planning a pregnancy